C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
1 other identifier
observational
3,392
0 countries
N/A
Brief Summary
The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2007
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2008
CompletedFirst Submitted
Initial submission to the registry
May 29, 2008
CompletedFirst Posted
Study publicly available on registry
June 3, 2008
CompletedApril 9, 2009
April 1, 2009
May 29, 2008
April 8, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin
3 visits within 10 weeks
Secondary Outcomes (1)
Tolerability of CRESTOR-therapy
3 visits within 10 weeks
Study Arms (1)
Pt with hypercholesteremia
Patients treated with CRESTOR because of hypercholesteremia
Eligibility Criteria
Statin-naive patients and unsuccessfully treated with other (non rosubastatin) statins patients
You may qualify if:
- Patients with hypercholesteremia who was never treated with statins before
- Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 29, 2008
First Posted
June 3, 2008
Study Start
February 1, 2007
Study Completion
January 1, 2008
Last Updated
April 9, 2009
Record last verified: 2009-04